Each week our clinical team selects the most important new publications and distils each one into 50 words, so you get the signal without the noise.
PLoS Med.5 August 2026Cardiovascular health
Cardiovascular outcomes and safety associated with statin therapy for primary prevention in older adults with type 2 diabetes
Target trial emulation using Hong Kong electronic health records: adults with type 2 diabetes, LDL-C ≥2.6 mmol/L, and no prior cardiovascular disease. Statin initiation was associated with fewer cardiovascular events and lower all-cause mortality in those aged 75–84 and 85 and over, without excess muscle-related or liver events.
Diagnostic accuracy of computed tomography in patients with non-specific symptoms of cancer referred directly from general practice
This Danish study assessed cancer prevalence and use of contrast-enhanced CT of the thorax, abdomen and pelvis for non-specific symptoms referred from general practice. Referrals rose five-fold from 2012–2019. Cancer was found in 13% of patients. Twelve false negatives gave LR 0.15, so CT alone shouldn’t guide decisions.
Comparative effects of drugs for adults with overweight or obesity
Randomised trial compared obesity drugs against lifestyle, placebo or other agents over 12 weeks. Tirzepatide produced the greatest mean weight loss (14.9%), narrowly ahead of CagriSema (14.8%); oral semaglutide (10.9%), orforglipron (9.9%), injectable semaglutide (9.8%) and phentermine-topiramate (8.1%) followed. Larger losses were accompanied by more harms, discontinuation, and little quality-of-life gain overall.
The Royal College of Paediatrics and Child Health's updated State of Child Health report finds children's health across the UK worsening or stalled against most of its 12 indicators, hitting deprived communities hardest. Primary-care-relevant metrics include two-dose MMR coverage at 84% by age five, below the 95% target, alongside rising childhood obesity and worsening mental health.
GLP-1 receptor agonists, licensed for obesity and type 2 diabetes but not for eating disorders, are being investigated in binge eating disorder. A large evidence review found their use associated with lower binge-eating severity and reduced loss of control around food in adults with obesity. Long-term benefit remains uncertain, and reviewers flagged a possible increase in dietary restraint.
Point-of-care biomarkers or laboratory-based tests to reduce antibiotic prescribing for COPD exacerbations: a literature review and meta-analysis in primary care
Seven studies were reviewed. CRP point-of-care testing significantly reduced antibiotic prescribing for COPD exacerbations (odds ratio 0.41), with no apparent cost to patient safety or quality of life, though certainty was low. Data on procalcitonin, around ten times more expensive, were insufficient. Authors called for conflict-free double-blind RCTs.
Exploring the implementation and integration of structured medication reviews in primary care: a qualitative evaluation using normalisation process theory
18 clinical pharmacists and five service leads across seven NHS England regions were interviewed. They found structured medication reviews often undermined by patients not being told in advance, high workload, weak leadership buy-in, and limited training, particularly consultation skills for deprescribing. Reviews identified unmet needs and prevented admissions.
Primary care accessibility for complex mental health difficulties
In a qualitative study of 19 adults with complex mental health difficulties across seven GP practices in deprived areas, three themes emerged: searching for an understanding of the self, the condition itself creating barriers to care, and the precarity of self-care and help-seeking. The authors challenge the assumption that this group lacks health literacy, pointing instead to a need for services to collaborate better.
The first FDA-cleared plasma test for Alzheimer amyloid pathology may produce many more false positives than its label suggests. In a JAMA Neurology cross-sectional study, the cut points showed just 23% specificity against PET or CSF, against a claimed 91%, misclassifying 40% of amyloid-negative people. The reagent variation behind this prompted a class 2 recall. A cautionary note as blood biomarkers move toward clinics.
Waist Circumference as a CVD Screening Tool in Primary Care
This Dutch mixed-methods study found waist circumference is rarely recorded in primary care, yet measuring it could help. Among 6671 adults, it would identify 89% at intermediate and 93% at high predicted cardiovascular risk, including non-obese patients whose raised waist BMI-based screening would otherwise miss.
Retatrutide as monotherapy in early type 2 diabetes (TRANSCEND-T2D-1)
Retatrutide, an investigational GIP, GLP-1 and glucagon triple receptor agonist, was given as monotherapy to 537 adults with recent-onset type 2 diabetes inadequately controlled on diet and exercise (TRANSCEND-T2D-1). At 40 weeks HbA1c fell by 1.94% on the 12 mg dose versus 0.81% with placebo, from a baseline of 7.9%, with weight down 16.8%. Investigational; not UK-licensed.
Mazdutide is a once-weekly dual agonist (GLP-1 AND glucagon), and is, currently, only approved in China.
GLORY-2 was a double-blind, placebo-controlled, phase 3 randomised trial evaluating its efficacy and safety for weight reduction in Chinese adults with obesity.
461 participants across 27 hospitals were randomised 2:1 to mazdutide 9 mg or placebo over 60 weeks.
Mean weight reduction was 16.65% with mazdutide vs. 1.50% with placebo, and 84.3% vs. 33.1% achieved at least 5% loss, meeting both co-primary outcomes.
The reduction was clinically meaningful, though gastrointestinal events were the most common adverse reactions.
Patients with advanced CKD are normally excluded from anticoagulant trials because of bleeding risk, leaving the medication’s effects on CV effects unclear.
TRACK, a randomised, double-blind, placebo-controlled trial, tested whether taking low-dose rivaroxaban twice daily reduced major CV events in CKD stage 4 or 5, including dialysis patients.
Among 1458 patients, CV events occurred in 22.6% on rivaroxaban, versus 20.7% on placebo. Major bleeding was higher with rivaroxaban (8.8% versus 6.0% on placebo). Low-dose rivaroxaban did not reduce cardiovascular events, but increased rates of major bleeding.
Beyond Diabetic Kidney Disease: Finerenone Takes On Glomerular CKD
The FIND-CKD Ph3 trial evaluated whether finerenone, a nonsteroidal once-daily mineralocorticoid receptor antagonist, can slow loss of kidney function in patients with glomerular diseases. What they found for patients treated with finerenone (446) versus placebo (457): A slower annual eGFR decline of −3.50 vs –4.23 mL/min/1.73 m2 per year, difference = 0.73; A reduced albuminuria of 42% at month 12; A lowered risk of kidney failure or a decline of 40% or more in eGFR, with a hazard ratio of 0.74; Effects were consistent across disease subtypes
PLEASE NOTE: Findings are exploratory this study was not powered for kidney outcomes and some diagnosis lacked biopsy confirmation.
ACHIEVE-5 oral GLP-1 RA improves A1c on top of basal insulin
ACHIEVE-5 randomised 546 adults with type 2 diabetes inadequately controlled on insulin glargine to once-daily oral orforglipron (3, 12 or 36 mg) or placebo for 40 weeks. All doses reduced HbA1c (1.58% to 1.88% versus 0.79%; P<0.001) and body weight (2.6% to 5.4% versus a 0.2% gain), without raising clinically significant hypoglycaemia.
ALIENTO and ARNASA: Safety and efficacy of astegolimab for COPD with frequent exacerbations
Across ALIENTO and ARNASA, 2,676 COPD patients were randomised to astegolimab every 2 weeks (Q2W) or 4 weeks (Q4W). Q2W reduced exacerbations by 15% in both trials, while Q4W showed 7% and 18% reductions respectively. Though not all comparisons reached significance, results support targeting the ST2/IL-33 pathway in COPD.
Cefepime-nacubactam and aztreonam-nacubactam versus imipenem-cilastatin for complicated UTI and uncomplicated pyelonephritis
A randomised trial of 614 patients compared three intravenous treatments over 5–14 days: cefepime-nacubactam, aztreonam-nacubactam and imipenem-cilastatin. Cefepime-nacubactam achieved 82% success, aztreonam-nacubactam 72%, and imipenem-cilastatin 61%. Both nacubactam-based combinations show promise as treatment options for Gram-negative complicated UTIs and acute pyelonephritis, particularly against antimicrobial-resistant strains.
Orforglipron for maintenance of body weight reduction
376 patients that completed 72 weeks of tirzepatide or semaglutide were randomised to oral orforglipron or placebo for 52 weeks. The tirzepatide cohort preserved 74.7% of weight reduction; semaglutide, 79.3%. Both converged at exactly 95.9 kg, raising concerns that it is a biologically defended weight. Orforglipron remains awaiting MHRA approval.
Polyendocrine metabolic ovarian syndrome — the new name for polycystic ovary syndrome
A multistep global consensus process gathered over 14,000 survey responses from patients and multidisciplinary health professionals across all world regions. Using modified Delphi methods and nominal group workshops, candidate names were tested across endocrine, metabolic, and reproductive domains. The result: consensus endorsement of polyendocrine metabolic ovarian syndrome.
Tirzepatide for maintenance of bodyweight reduction
SURMOUNT-MAINTAIN: a US-only phase 3b trial across 20 sites. 441 adults with obesity completed 60 weeks of active weight loss then continued subcutaneous tirzepatide or switched to placebo for 112 weeks total. Bodyweight change from baseline at week 112: −21.9% (maximum tolerated dose), −16.6% (5 mg), −9.9% (placebo), highlighting the importance of sustained optimal dosing.
Clinical trial data on zanidatamab, a targeted treatment for a rare and aggressive form of bile duct cancer, showed that people treated lived for an average of 18 months after taking the drug, significantly longer than those receiving standard chemotherapy. NICE recommended it for routine use on 7 May 2026 (TA1153).
Semaglutide for alcohol use disorder with comorbid obesity
Single-centre Copenhagen RCT randomised 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and BMI ≥30 to once-weekly semaglutide 2.4 mg or placebo, plus standard CBT, for 26 weeks. Semaglutide reduced heavy drinking days by 13.7 percentage points more than placebo (p=0.0015). Hypothesis-generating; not a licensed indication.
Prediagnostic prescription patterns in multiple sclerosis
UK CPRD case-control study of 9,662 MS cases and 56,455 matched controls used conditional logistic regression and Poisson regression to identify inflection points. Seven prescription categories (anxiety/depression, migraine, LUTS, UTI, sleep disorder, GI symptoms, and ED) showed elevated odds ratios in the 2 years pre-diagnosis, with inflection points 9–72 months pre-diagnosis.
Major commission on prevention, diagnosis and management of MASLD/MASH and alcohol-related liver disease across European primary care. UK-relevant policy framings on screening, AUDIT-C use and direct access fibrosis assessment.
Statin initiation and new-onset myasthenia gravis: multinational SCCS
Self-controlled case series across Hong Kong, UK and Japan analysed 2,267 MG cases. Pooled incidence rate ratio for new-onset MG was 2.66 (95% CI 1.28–5.55) in the first 6 months after statin initiation, 1.41 (1.01–1.95) at 6–12 months, with no excess risk beyond 12 months. Dose-dependent.
EULAR 2025 update: physical activity in inflammatory arthritis and osteoarthritis
Updated EULAR recommendations on physical activity in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and hip/knee osteoarthritis. Reinforces aerobic and resistance exercise as core treatment, addresses disease-specific considerations, and provides clinician guidance on counselling, dose, and safety. Direct relevance to GP and practice nurse review consultations.
Understanding risk stratification of chronic kidney disease: qualitative study in primary care
26 interviews and 4 focus groups across 20 UK practices. Awareness of CKD diagnostic criteria was high, but awareness of risk stratification tools was low. Time pressures and lack of incentivisation were identified as key barriers, alongside concerns about patient anxiety and over-medicalisation. Authors suggest education, pathways and automation as improvements.
FreeDM2: real-time CGM in basal-insulin-treated type 2 diabetes
FreeDM2 randomised 303 UK adults with basal-insulin-treated type 2 diabetes to real-time CGM versus fingerstick monitoring. At 32 weeks, CGM was associated with a 5 mmol/mol greater HbA1c reduction (62 vs 67 mmol/mol) and around 10% more time in range, with no increase in hypoglycaemia. Funded by Abbott.
Low-plastic diet and urinary phthalate/bisphenol levels (PERTH trial)
Australian RCT randomised participants to a low-plastic diet intervention or usual diet for 4 weeks. The intervention significantly reduced urinary concentrations of plastic-associated phthalates and bisphenols. Demonstrates that dietary modification can rapidly reduce measurable exposure to endocrine-disrupting chemicals. Useful evidence for patient-led discussions on environmental health.
SCOUT: four antibiotic regimens compared for uncomplicated UTI in women
In 768 Spanish primary care patients with uncomplicated lower UTI (dysuria, urgency, frequency, or suprapubic tenderness plus positive dipstick), nitrofurantoin 100mg tds for 5 days, pivmecillinam 400mg tds for 3 days, single-dose fosfomycin, and two-dose fosfomycin were compared. Authors concluded nitrofurantoin most effective, single-dose fosfomycin least effective. Open-label design.
J Gen Intern Med20 April 2026Cardiovascular Disease
ASCVD risk-enhancing factors and primary prevention statin use
US cross-sectional analysis examining how often risk-enhancing factors (family history, inflammatory disease, CKD, metabolic syndrome) are documented and how this influences statin initiation in patients with borderline or intermediate 10-year ASCVD risk. Highlights under-identification of risk-enhancers, particularly in women and younger adults, as a barrier to appropriate primary prevention.
Postpartum rectus diastasis management in primary care
Practical women's health refresher covering assessment, conservative management, when to refer for physiotherapy and surgical referral indications. Useful for GPs and nurses managing routine postnatal reviews.
BJGP20 April 2026Neurology
Prescription signals in the years before MS diagnosis
CPRD case-control of 9,662 UK MS cases and 56,455 matched controls. Seven prescription categories (including LUTS, UTI, migraine, GI, antidepressants, ED) were associated with subsequent MS, with odds ratios 3–7 times higher in the 2 years pre-diagnosis. Inflection points ranged 9–72 months pre-diagnosis, with wide confidence intervals.
Pirtobrutinib: take-at-home treatment for CLL recommended by NICE
Pirtobrutinib recommended as a take-at-home drug for people with chronic lymphocytic leukaemia (CLL) who have previously been treated with a Bruton's tyrosine kinase (BTK) inhibitor and for whom further BTK inhibitor treatment is not suitable. Final TA publication date TBC.
Structured medication reviews and prescribing in English primary care
ORCHID retrospective cohort: 82,285 of 635,698 eligible patients aged ≥65 received an SMR during April 2020–September 2022. SMRs were associated with both new prescriptions and cessation of ACE inhibitors, statins and antidepressants. Between 12.5% and 40% of potentially inappropriate drug combinations were corrected within three months.
Interim diagnoses and missed cancer diagnoses in primary care
Qualitative study: 35 GPs, 3 other clinicians and 3 administrators across 31 practices in Southern England. Interim non-cancer diagnoses were reported to occur with non-specific symptoms and remote consultations. Participants described using safety-netting and an informal "three strikes and you're in" rule, and valued colleagues offering fresh perspectives.
SABA overuse and major adverse cardiovascular events in asthma
Population-based cohort study examined association between short-acting β2-agonist overuse (≥3 canisters/year) and MACE in adults with asthma. SABA overuse was associated with increased risk of MACE compared with appropriate use, with a dose-response relationship. Adds cardiovascular signal to the established mortality and exacerbation risks of SABA overreliance.
NG12 Major Update: Age-adjusted CA125 thresholds for ovarian cancer detection
Age-adjusted CA125 thresholds introduced for ovarian cancer detection, replacing the universal 35 IU/ml cut-off for adults aged 40 and over. CA125 no longer recommended in isolation for adults aged 39 and under — direct access ultrasound advised instead. New endometrial cancer recommendations for post-menopausal bleeding (1.5.12, 1.5.14, 1.5.15) and a new weight loss recommendation for adults aged 60 and over (1.13.2).
ApoB outperforms traditional lipid markers for ASCVD risk in younger adults
Pooled cohort of 10,519 US adults (CARDIA, FHS Offspring, MESA) followed median 21 years. ApoB associated with ASCVD even after adjustment for traditional lipids, with stronger association in adults 18–39 (AHR 1.53) than ≥40 (AHR 1.13). Adding apoB to PREVENT improved 10- and 30-year risk reclassification.
IDSA 2025 update: antivirals for mild-to-moderate COVID-19 in adults
Updated IDSA guideline on outpatient antiviral treatment for non-hospitalised adults with mild-to-moderate COVID-19. Reviews nirmatrelvir-ritonavir, molnupiravir, and remdesivir indications, risk-stratification, and drug interactions. Recommendations reflect current variant landscape and reduced relative benefit in vaccinated low-risk patients. Relevant for primary care prescribing decisions and risk-based eligibility.
